Anika Therapeutics, Inc. Business Acquisition, Pro Forma Revenue
Anika Therapeutics, Inc. (ANIK) reported Business Acquisition, Pro Forma Revenue of $72.44 million for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-06.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2023-03-16
- Anika Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2021-06-30 was $38.15M, a 24.34% increase year-over-year.
- Anika Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2021-03-31 was $34.29M, a 12.85% decline year-over-year.
- Anika Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2020-12-31 was $32.69M, a 23.42% decline year-over-year.
- Anika Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2020-09-30 was $31.69M, a 20.59% decline year-over-year.
- Anika Therapeutics, Inc. business acquisition, pro forma revenue for fiscal 2020 was $134.41M, a 14.78% decline from fiscal 2019.
- Anika Therapeutics, Inc. business acquisition, pro forma revenue for fiscal 2019 was $157.73M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2021-06-30 | $38.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $72.44M 10-Q · filed 2021-08-06 | $105.13M derived: sum of 3 quarters · filed 2023-03-16 | $136.82M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $34.29M 10-Q · filed 2021-05-07 | $66.98M derived: sum of 2 quarters · filed 2023-03-16 | $98.67M derived: sum of 3 quarters · filed 2023-03-16 | $129.35M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $32.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $64.38M derived: sum of 2 quarters · filed 2023-03-16 | $95.06M derived: sum of 3 quarters · filed 2023-03-16 | $134.41M 10-K · filed 2023-03-16 |
| 2020-09-30 | $31.69M 10-Q · filed 2020-11-05 | $62.37M derived: sum of 2 quarters · filed 2020-11-05 | $101.72M 10-Q · filed 2021-11-05 | $144.41M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | $30.68M 10-Q · filed 2020-08-07 | $70.03M 10-Q · filed 2021-08-06 | $112.71M derived: sum of 3 quarters · filed 2022-03-11 | $152.62M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-03-31 | $39.35M 10-Q · filed 2021-05-07 | $82.03M derived: sum of 2 quarters · filed 2022-03-11 | $121.94M derived: sum of 3 quarters · filed 2022-03-11 | $162.37M derived: sum of 4 quarters · filed 2022-03-11 |
| 2019-12-31 | $42.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $82.59M derived: sum of 2 quarters · filed 2022-03-11 | $123.02M derived: sum of 3 quarters · filed 2022-03-11 | $157.73M 10-K · filed 2022-03-11 |
| 2019-09-30 | $39.91M 10-Q · filed 2020-11-05 | $80.34M derived: sum of 2 quarters · filed 2020-11-05 | $115.05M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $40.43M 10-Q · filed 2020-08-07 | $75.13M 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |